AstraZeneca PLC
AZN
$73.95
$0.861.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.80% | 22.76% | 18.14% | 10.16% | 4.49% |
| Total Depreciation and Amortization | 4.44% | 3.30% | 3.22% | 2.30% | -1.38% |
| Total Amortization of Deferred Charges | -28.57% | -28.57% | -28.57% | -4.11% | -4.11% |
| Total Other Non-Cash Items | 179.23% | 167.86% | 149.18% | 94.32% | 44.74% |
| Change in Net Operating Assets | -333.26% | -117.63% | -397.67% | -187.53% | -25.20% |
| Cash from Operations | 21.00% | 34.96% | 14.65% | 9.37% | 8.70% |
| Capital Expenditure | -34.69% | -26.45% | -41.37% | -44.12% | -44.63% |
| Sale of Property, Plant, and Equipment | -79.66% | -95.00% | -58.33% | -86.36% | -85.54% |
| Cash Acquisitions | 68.77% | -97.16% | -244.13% | -254.33% | -233.39% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.72% | 20.94% | -34.16% | -79.53% | -18.59% |
| Cash from Investing | 20.14% | -30.38% | -96.36% | -143.39% | -101.78% |
| Total Debt Issued | -90.01% | -73.24% | 63.24% | 96.44% | 107.57% |
| Total Debt Repaid | 46.13% | -55.37% | 4.05% | -6.50% | -21.99% |
| Issuance of Common Stock | 8.33% | 14.29% | 15.15% | 20.00% | 24.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.62% | -10.66% | -3.30% | -3.33% | 0.00% |
| Other Financing Activities | 114.21% | 114.43% | 7.79% | 7.79% | 0.34% |
| Cash from Financing | -216.19% | -248.13% | 39.15% | 45.49% | 58.58% |
| Foreign Exchange rate Adjustments | 120.00% | 76.84% | -55.00% | 56.67% | 29.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -70.56% | -233.32% | 39.88% | -142.49% | 21.70% |